BioNTech SE Q2 2021 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Zhiqiang Shu - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst : I'd like to also ask at the booster opportunity here. Given the waning protection of the vaccine, I think a critical question is about the T cell response. Ugur, can you talk about, based on our current understanding what is the role of T cell response, particularly memory T cells and B cells here, in terms of conferring the protection (inaudible)? Also, I want to ask about the oncology pipeline regarding FixVac. How should we think about the look across -- read across different cancer types? Is that related to pathology of the tumor types or related to the selection of neoantigen?

Question: Zhiqiang Shu - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst : Yes. The same question I'd like to ask about the kind of the read cross different tumor types regarding your FixVac. Obviously, you have positive -- quite encouraging data in melanoma. And how should we think about other tumor types?

Question: Arlinda Anna Lee - Canaccord Genuity Corp., Research Division - Analyst : I was also curious about the booster and maybe your broader strategy on the COVID situation. I know it's fluid, but on the multivalent, could that include other SARS-CoV-2 proteins? And I saw that you guys were looking at adding for additional variants. And then I guess maybe as a follow-up to that, how easily can your manufacturing setup change to manufacture some of these variants?